Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· April 26, 2026

Is Sanofi (ENXTPA:SAN) Offering Value After Recent Share Price Weakness

View original at finance.yahoo.com

Is Sanofi (ENXTPA:SAN) Offering Value After Recent Share Price Weakness Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

Analyst and extrapolated forecasts project Sanofi's free cash flow to reach €12.72 billion in 2030, with intermediate annual projections through 2035
60% confidence
Sanofi's -9.5% return over the last year is lagging behind its pharmaceutical sector peers
60% confidence
Sanofi is undervalued by 68.7% according to a 2-Stage Free Cash Flow to Equity DCF model, with an estimated intrinsic value of €255.70 per share versus a current price of approximately €80.08
60% confidence
Sanofi currently has a value score of 6 out of 6
60% confidence
There are 230 or more high quality undervalued stocks available to discover on Simply Wall St's platform
60% confidence
Simply Wall St is trusted by over 7 million individual investors worldwide
60% confidence
Recent sentiment around Sanofi has been mixed due to broader pharmaceutical sector dynamics, regulatory developments, and shifting investor attention within healthcare
60% confidence

Data points we hold from this source

Sanofi · margin

-68.7 percent